Stream Link: https://event.arraylive.com/app/login/1c12ab15-627c-4ca4-8dbf-8bf932aaa31d/virtualattendee
This CE activity is broadcast in partnership with the Hematology/Oncology Pharmacy Association.
Program Description
Recent evidence suggests a potential shift in treating renal cell carcinoma (RCC), both in advanced and early stages. Combination therapies involving immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in advanced and metastatic RCC have become the standard of care. Several advantages exist with ICI-TKI combination therapy, such as synergistic effects stemming from different mechanisms of action, improved survival outcomes, and potential for delayed development of resistance. Faculty experts leading this panel discussion will discuss strategies to facilitate the use of ICI-TKI combination therapy in RCC according to evidence-based guidelines. Throughout the discussion, participants can examine the broader use of ICIs and TKIs through interactive patient cases, considering factors that may indicate benefit from adjuvant therapy, improved management of treatment-related adverse effects, or the most effective selection of combination therapy and subsequent treatment.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 15, 2025
Expiration date: July 15, 2025
Time to complete activity: 1.5 hours
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify first-line and subsequent treatment options for advanced clear cell renal cell carcinoma (ccRCC), considering clinical evidence, patient preferences, and sequencing
- Examine key counseling considerations for patients receiving adjuvant treatment in ccRCC, emphasizing the differences compared with counseling for those with metastatic disease
- Analyze recent clinical trial data on advanced non-ccRCC to understand the efficacy and safety of emerging treatment approaches and their impact on current clinical practice
- Employ strategies for identifying and managing treatment-related toxicities in RCC treatment, ensuring timely interventions and optimal outcomes
Candy Peskey, PharmD, BCPS, BCOP
Oncology/Hematology Infusion Center Pharmacist
Mayo Clinic Cancer Center
Rochester, Minnesota
Katie P. Morgan, PharmD, BCOP, CPP
Clinical Oncology Pharmacist
Department of Pharmacy
University of North Carolina Medical Center
Chapel Hill, North Carolina
Assistant Professor
Department of Practice Advancement and Clinical Education
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, North Carolina
Kristen Nymberg, PharmD, BCOP
Clinical Pharmacy Specialist, Genitourinary Oncology
The James Cancer Hospital at The Ohio State Wexner Medical Center
Columbus, Ohio
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-044-L01-P. The activity is available for CE credit through July 15, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Candy Peskey, PharmD, BCPS, BCOP, has the following financial relationship with a commercial interest to disclose:
Stock: Novartis.
Kristen Nymberg, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Advisory Board: Astellas Pharma Global Development Inc and Seagen Inc.
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Katie P. Morgan, PharmD, BCOP, CPP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms